Back to News & Events

SBIR/STTR Commercialization Readiness Pilot (CRP) Program Deadlines

The newly re-authorized Commercialization Readiness Pilot (CRP) program is now accepting applications from previously or currently HHS-funded SBIR and STTR Phase II and Phase IIB awardees.

NHLBI open and accepting applications from NHLBI grantees for the September 5th NIH SBIR/STTR receipt date; HHS/NIH general applications will be accepted from August 5, 2019 until April 6, 2022 via standard due dates.

CPR can provide over $3 million in additional funding to facilitate the commercialization transition for projects, and support work that is not typically supported through SBIR/STTR Phase II or Phase IIB awards, including:

– Preparation of documents for a Food and Drug Administration (FDA) submission
– Development of an intellectual property strategy
– Investigational New Drug (IND)-enabling studies
– Clinical studies
– Manufacturing costs
– Regulatory assistance
– Subcontracted work to other institutions, including contract research organizations (CRO)
– A combination of services.

Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the Small Business Concern (SBC) is expected to maintain oversight and management of the R&D throughout the award. Please note, this re-authorization includes (3) separate Funding Opportunity Announcements (FOAs) with varying participating NIH Institutes and Centers. Learn more here: https://sbir.nih.gov/funding#crp

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4488
                    [post_author] => 4
                    [post_date] => 2024-10-24 10:45:00
                    [post_date_gmt] => 2024-10-24 14:45:00
                    [post_content] => 

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2024-12-05 11:35:07 [post_modified_gmt] => 2024-12-05 16:35:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 3415 [post_author] => 3 [post_date] => 2020-01-13 14:10:26 [post_date_gmt] => 2020-01-13 14:10:26 [post_content] => MicroRid Technologies Inc. has received a five year, $4 million, Peer Reviewed Medical Research Program (PRMRP) Technology/Therapeutic Development Award, which is administered by the Department of Defense office of Congressionally Directed Medical Research Programs (CDMRP). The company, founded by Center for Biotechnology BioEntrepreneur-in-Residence Dr. Brian McCarthy and Stony Brook University Renaissance School of Medicine Professor Maurizio Del Poeta, is researching the development of small-molecule anti-fungal drugs.The Center for Biotechnology is also supporting company technology development efforts via our REACH program. The company will work with Stony Brook University on aspects of the project, engaging with Dr. Del Poeta as well as Dr. Iwo Ojim from the department of Chemisty. The goal of the project, titled “The Research and Development of New Antifungals” is to develop / optimize compounds that inhibit fungal specific targets and perform preclinical development that will help prepare the company for their Investigational New Drug filing with the FDA. [post_title] => MicroRid Technologies Receives $4M Award [post_excerpt] => MicroRid Technologies Inc. has received a five year, $4 million, PRMRP award. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => microrid-4m-award-2020 [to_ping] => [pinged] => [post_modified] => 2020-01-13 14:10:26 [post_modified_gmt] => 2020-01-13 14:10:26 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3415 [menu_order] => 80 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 3820 [post_author] => 4 [post_date] => 2021-09-20 15:59:29 [post_date_gmt] => 2021-09-20 15:59:29 [post_content] =>

NYSTAR and FuzeHub invite you to the New York State Innovation Summit on November 8-9, 2021 at the Turning Stone in Verona, NY. This multi-day event for NYS organizations that want to showcase and discover new and emerging technologies that support innovation and drive business growth. Whether you’re a startup, an economic developer, or an established manufacturer, the NYS Innovation Summit is for you.

The 2021 New York State Innovation Summit will showcase companies and researchers at the forefront of emerging technologies and new advancements in production capabilities. This event celebrates New York State leadership in technology-led economic growth with experts in biotechnology, new materials, energy innovation, and artificial intelligence that will explore current technology convergence opportunities, ways to accelerate commercialization, and issues of manufacturing sustainability.

This year’s Innovation Summit includes the New York State Commercialization Competition and speakers from top companies such as Cree, Plug Power, Velan Studios and Verizon 5G Labs.

For more information, or to register, visit nysinnovationsummit.com.

[post_title] => New York State Innovation Summit [post_excerpt] => NYSTAR and FuzeHub present the New York State Innovation Summit on November 8-9, 2021 at the Turning Stone in Verona, NY. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => new-york-state-innovation-summit [to_ping] => [pinged] => [post_modified] => 2022-08-22 13:09:12 [post_modified_gmt] => 2022-08-22 13:09:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3820 [menu_order] => 37 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 4032 [post_author] => 4 [post_date] => 2023-03-02 16:46:18 [post_date_gmt] => 2023-03-02 16:46:18 [post_content] =>

A second-generation taxane conjugate in a nanoemulsion formulation (called NE-DHA-SBT-1214) developed by Stony Brook University Distinguished Professor Iwao Ojima in his chemistry laboratory and through the Institute of Chemical Biology & Drug Discovery (ICB&DD) and licensed to Dr. James Egan, has received a $24 million investment to be taken to phase 2a development. Preclinical results have persuaded TVM Capital Life Science to invest in the technology via Recurv Pharma.

The VC fund will invest up to $24 million in Recurv through its project-focused company (PFC) investment objective, an initiative focused on backing first or best-in-class candidates that are clearly differentiated from the competition or add clinical value. Read More on Fierce Pharma and via SBU News.

[post_title] => Anti-Cancer Agent Developed at SBU Shows Great Promise Against Tumors, Receives $24M Investment [post_excerpt] => TVM Capital Life Science to invest $24M in Recurv Pharma to develop an SBU technology. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => anti-cancer-agent-developed-at-sbu-shows-great-promise-against-tumors-receives-24m-investment [to_ping] => [pinged] => [post_modified] => 2024-08-22 11:35:16 [post_modified_gmt] => 2024-08-22 15:35:16 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4032 [menu_order] => 7 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4488 [post_author] => 4 [post_date] => 2024-10-24 10:45:00 [post_date_gmt] => 2024-10-24 14:45:00 [post_content] =>

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2024-12-05 11:35:07 [post_modified_gmt] => 2024-12-05 16:35:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 259 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.

More Information

MicroRid Technologies Receives $4M Award

More Information

New York State Innovation Summit

More Information

Anti-Cancer Agent Developed at SBU Shows Great Promise Against Tumors, Receives $24M Investment

More Information